Cyclosporine

證據等級: L5

預測適應症: 7 個

Cyclosporine: From Organ Transplant Rejection to Chronic Granulomatous Disease

One-Sentence Summary

Cyclosporine is a well-established calcineurin inhibitor and immunosuppressant, widely used in solid organ transplantation and a range of autoimmune conditions. The TxGNN model predicts it may be effective for Chronic Granulomatous Disease (CGD), Autosomal Recessive Form, with 1 clinical trial and 1 publication currently available — both situated in the context of hematopoietic stem cell transplantation (HSCT) used to cure CGD.

Quick Overview

Item	Content
Original Indication	Not available in current dataset (no DINs found)
Predicted New Indication	Granulomatous Disease, Chronic, Autosomal Recessive (CGD)
TxGNN Prediction Score	99.68%
Evidence Level	L3
Canada Market Status	Not Marketed (per current dataset — likely a data gap)
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on well-established pharmacological knowledge, cyclosporine is a calcineurin inhibitor that blocks T-cell activation by preventing calcineurin from dephosphorylating NFAT transcription factors, thereby suppressing interleukin-2 (IL-2) and other pro-inflammatory cytokines. This broad immunosuppressive effect underpins its use in transplantation, rheumatoid arthritis, psoriasis, and nephrotic syndrome.

Chronic Granulomatous Disease (CGD) is a primary immunodeficiency caused by inherited defects in the NADPH oxidase complex, leaving phagocytes unable to generate the reactive oxygen species needed to kill ingested pathogens. Patients suffer from recurrent, life-threatening bacterial and fungal infections and granuloma formation. Hematopoietic stem cell transplantation (HSCT) is currently the only curative therapy for CGD, and cyclosporine is a cornerstone of standard GvHD prophylaxis in that context.

The mechanistic link is therefore indirect: cyclosporine does not correct the NADPH oxidase defect itself, but rather suppresses alloreactive T-cell responses to prevent graft-versus-host disease — enabling HSCT to succeed and thus cure CGD. This is a well-accepted clinical use pattern rather than a novel repurposing hypothesis in the strict sense, which partly explains the high TxGNN score. Whether cyclosporine has a role as a direct immunomodulatory agent in CGD outside of HSCT remains an open research question.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01917708	Phase 1	Completed	10	Assessed tolerability of abatacept added to cyclosporine + mycophenolate mofetil as GvHD prophylaxis in children undergoing unrelated donor HSCT for serious non-malignant diseases (including CGD); participants followed for 2 years. Cyclosporine served as background standard-of-care, not the primary investigational agent.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22078471	2012	Retrospective Cohort	J Allergy Clin Immunol	Demonstrated excellent survival outcomes after both matched related and unrelated donor HSCT for CGD, supporting HSCT — and by extension standard GvHD prophylaxis regimens including cyclosporine — as an effective curative strategy for this disease.

Canada Market Information

No Drug Identification Numbers (DINs) were found in the current regulatory dataset for cyclosporine. This almost certainly reflects a data collection gap rather than true absence from the Canadian market: cyclosporine is a long-established reference drug available under brand names such as Neoral® and Sandimmune® in many jurisdictions. Regulatory data should be retrieved directly from Health Canada’s Drug Product Database before any market access assessment proceeds.

Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug–drug interaction data were available in the current evidence pack.

Note: Cyclosporine is known to carry significant safety considerations including nephrotoxicity, hepatotoxicity, hypertension, neurotoxicity, and a large number of clinically important drug–drug interactions (particularly with CYP3A4 substrates and P-glycoprotein modulators). Obtaining the full prescribing information is rated Blocking severity in the current data gap assessment and must be resolved before any clinical safety evaluation can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The available evidence supports cyclosporine’s role as standard GvHD prophylaxis within HSCT for CGD — an indirect and already-established clinical use pattern rather than a novel repurposing application. The evidence base is limited to one small Phase 1 trial (n = 10, primary drug = abatacept) and one retrospective cohort study focused on HSCT outcomes. Significant blocking data gaps remain in safety information and regulatory status, preventing entry into a formal safety screening stage.

To proceed, the following is needed:

Regulatory verification: Confirm Health Canada DIN status and retrieve approved prescribing information for cyclosporine products (Neoral®, Sandimmune®, generic equivalents)
Safety data: Obtain TFDA/Health Canada package insert to extract warnings, contraindications, and drug interactions — currently a Blocking data gap
MOA clarification: Retrieve full mechanism of action from DrugBank (DB00091) to support mechanistic analysis
Repurposing hypothesis refinement: Clearly distinguish between (a) cyclosporine as standard GvHD prophylaxis enabling curative HSCT in CGD (already established practice, not a new repurposing opportunity) vs. (b) cyclosporine as a direct immunomodulatory agent in CGD patients not undergoing HSCT (genuinely novel, but currently unsupported by evidence)
Prospective evidence: If hypothesis (b) is pursued, a proof-of-concept study or systematic review of any existing off-label use would be needed to elevate evidence beyond L3
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.